Global Microbiome Therapeutics & Diagnostics Market Analysis | Healthcare & Medical Research
This report focuses on a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics.
• An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
• Detailed account of the microbiome industry market by geography, indication and company profiles.
• Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
• SWOT analysis of the global market.
• Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW.
Get the sample page of the report: https://www.jsbmarketresearch.com/sample-request/global-microbiome-therapeutics-diagnostics-market-analysis
Executive Summary
The global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. Our analysis indicates that North America holds the lions share of the microbiome therapeutic and diagnostic market in 2018 at $x million.
This compares to $x million in Europe, $x million in Asia Pacific, and $x million in the Middle East. By 2023, North America will continue to dominate the market, with a revenue of $x billion, compared to $x million in Europe, $x million in Asia Pacific, and $x million in the Middle East.
Six key therapeutic areas that the microbiome therapeutic and diagnostic market is sub-divided:
The gastrointestinal therapeutic market is the most dominant, demanding $x million in revenue in 2018, which will rise to $x million by 2023. This is mainly due to disease states such as Clostridium difficile infection, Crohn’s disease, ulcerative colitis and gastroenteritis.
Second to this, metabolic therapeutics has a x% market share and in 2018 is worth $x million, and will hit $x million by 2023. The main indications within this field include diabetes, obesity and non alcoholic liver disease.
The microbiome cancer therapeutics market is currently worth $x million, or x% of the total market. Our analysis indicate that this will rise to $x million in 2023 and remain in third place behind metabolic and gastrointestinal disorders.
The neurological market includes dominant indications such as Alzheimer’s, Parkinson’s, depression, anxiety disorders and autism. The neurological microbiome diagnostic market is currently worth $x million, which will increase to over $x million by 2023.
Autoimmune disorders such as multiple sclerosis currently demand $x million in the microbiome therapeutics market, which will increase to $x million by 2023. The smaller diagnostic market is currently worth $x million, and will grow to $x million in 2023.
Skin disorders such as acne, dermatitis and psoriasis currently have about x% share in the overall microbiome market, and the therapeutics area is worth $x million in 2018. This is set to rise to $x million by 2023. The corresponding diagnostics area will hit $x million in 2023, from $x million in 2018.
Competitive Landscape
The main therapeutic competitors within the microbiome industry are as follows:
• Johnson & Johnson
• Novartis International
• Abbvie
• Takeda
• Merck & Co.,
More specifically, companies involved in C. difficile infection include Actelion Pharmaceutical, Assembly Biosciences, AzurRx, Da Volterra, Pfizer, Merck, Merus, Rebiotix, Sanofi, Seres Therapeutics, Synthetic Biologics and Summit Therapeutics. Companies within the IBS-Constipation market include Ardelyx, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics and Takeda. Within the pertussis market GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation and Sanofi are major players. BioMarin Pharmaceutical, Synthetic Biologics, Codexis and Synlogic are involved in the PKU market.
The main players of the market:
• Metabiomics - Colon Polyp and Colon Cancer Test
• Origin Sciences - Colorectal Cancer (CRC) Test
• Enterome/AbbVie - IBD110
Click to view full market research report at: https://www.jsbmarketresearch.com/healthcare-medical/global-microbiome-therapeutics-diagnostics-market-analysis
Latest related reports: https://www.jsbmarketresearch.com/healthcare-medical/united-kingdom-dental-membrane-procedures-outlook-to-2025
ABOUT JSB MARKET RESEARCH –
JSB market research is one of the most significant databases of online market researches and intelligence reports and services. we specialize in providing market research reports for various industries. the online portal for marketing research deals with access to global market data and assists in providing expert.
Contact Details:
Phone: +919987295242
Website: www.jsbmarketresearch.com
Email: - enquiry@jsbmarketresearch.com